Showing 401-410 of 3714 results for "".
- Pilot Study Supports Once-Daily Isotretinoin for Acne Treatmenthttps://practicaldermatology.com/news/pilot-study-supports-once-daily-isotretinoin-acne-treatment/2463088/Micronized isotretinoin administered once per day without food was effective and well-tolerated for the treatment of severe nodular acne, new study results indicate. Researchers for the pilot study focused on and evaluated a regimen of once-daily micronized isotretinoin (0.4 to 0.8 mg/kg/day) witho…
- Study Highlights Dermatology Resident Views on Sensitive Skin Educationhttps://practicaldermatology.com/news/study-highlights-dermatology-resident-views-sensitive-skin-education/2462717/In a recent article published in the Journal of Drugs in Dermatology, researchers shed light on the educational exposure and perspectives of dermatology resident physicians regarding sensitive skin. Sensitive skin, typified by symptoms such as redness, itching, burning, and stinging triggered by in…
- Probiotics Top List of Acne Supplement Ingredientshttps://practicaldermatology.com/news/probiotics-top-list-acne-supplement-ingredients/2462477/The most popular dietary supplements for acne contain probiotics, diindolylmethane, vitamin A, vitamin B complex, and zinc, according to a review of 13 supplements. Although surveys have shown that many acne patients opt for dietary supplements as adjunctive treatments, these products are not subje…
- Ceramide and Niacinamide-Containing Moisturizer Safe, Effective with Topical Acne Treatmenthttps://practicaldermatology.com/news/study-reveals-ceramide-and-niacinamide-containing-moisturizer-enhances-topical-acne-treatment/2462234/New research suggests that a moisturizer containing ceramides and niacinamide (CCM) significantly improved lesions from acne vulgaris when combined with anti-acne medication. "Dermatologists often suggests using moisturizers for a wide range of skin problems initiated by acne treatment, such as CC…
- Roflumilast Formulations Show Favorable Tolerability Across Several Trials: Analysishttps://practicaldermatology.com/news/roflumilast-formulations-show-favorable-tolerability-across-several-trials-analysis/2462229/Investigator- and patient-rated assessments indicated that topical roflumilast was tolerable and did not cause discomfort, according to a new analysis of data from several clinical trials. “Formulating a topical medication that does not irritate the skin is an important factor contributing to pati…
- FDA Approves ZELSUVMI™ as a First-in-Class Medication for Molluscum Contagiosumhttps://practicaldermatology.com/news/fda-approves-zelsuvmi-as-a-first-in-class-medication-for-molluscum-contagiosum/2462203/Ligand Pharmaceuticals Incorporated today announced that the US Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older.1 The FDA approved ZELSUVMI as …
- In the Lab With Boston University Melanoma Researcher Deborah Langhttps://practicaldermatology.com/news/in-the-lab-with-boston-university-melanoma-researcher-deborah-lang-phd/2462120/Deborah Lang, PhD, associate professor of dermatology at Boston University Chobanian & Avedisian School of Medicine, received a two-year, $300,000 Discovery Boost Grant from the American Cancer Society (ACS) for her research project “Exploring roles for PAX3 in regulating gene expression on a post …
- Psoriasis Pipeline Update: Will An Oral IL-23 Inhibitor Be the Next Psoriasis Blockbuster?https://practicaldermatology.com/news/psoriasis-pipeline-update-will-an-oral-il-23-inhibitor-be-the-next-psoriasis-blockbuster/2462098/Investigational JNJ-2113 is a novel oral interleukin (IL)-23R antagonist peptide that binds with high affinity to the IL-23R. It is the first and only targeted oral peptide designed to block the IL-23 receptor, which underpins the inflammatory response in psoriasis and other IL-23-mediated diseases…
- Positive Phase 2a Data Shown for MC2-32, a Novel HSP90 Inhibitor in HShttps://practicaldermatology.com/news/positive-phase-2a-data-shown-for-mc2-32-a-novel-hsp90-inhibitor-in-hs/2462058/MC2-32 (previously RGRN-305), a first-in-class, oral therapy HSP90 inhibitor, performed well in Hidradenitis Suppurativa (HS), according to Phase 2a results presented during a late-breaking session at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Berlin. The single c…
- American Hair Research Society to Host Hybrid Alopecia Areata Summit 12/10-11https://practicaldermatology.com/news/american-hair-research-society-to-host-hybrid-alopecia-areata-summit-1210-11/2461459/The Alopecia Areata Summit “New Pathways, New Treatments” organized by the American Hair Research Society will be held December 10-11 at the New York Academy of Medicine, 1216 5th Ave., New York, NY. The meeting is being co-Chaired by Angela M. Christiano, PhD, Columbia University; Wilma F. Bergfel…